GNPX · Genprex Inc
United States · RS rating 31 · As of 2026-11-03
| Price | 2.31 USD |
|---|---|
| 1-day change | +3.6% |
| RS rating (overall / 1M / 3M / 12M) | 31 / 27 / 10 / 17 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 34 / 49 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +33.2% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +72.5% |
| Market cap (USD) | $9.2M |